Also see: EMC, Jazz Pharma: Analysts' New RatingsEditor's Note: Green and red arrows refer to intraday stock price movement. NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES Amerigroup ( AGP) estimates, target cut at Oppenheimer. AGP estimates were reduced through 2012. Company continues to face higher costs. Outperform rating and new $69 price target. Ametek ( AME - Get Report) estimates higher at UBS. AME estimates increased through 2012, UBS said. Raising sales outlook, nudging margin estimates up. Maintain $47 price target and Neutral rating. Amgen ( AMGN - Get Report) estimates lowered at Oppenheimer through 2012. Company is seeing higher Neulasta and Enbrel sales. Outperform rating and $66 price target. Amgen ( AMGN - Get Report) estimates, target raised at UBS. Shares of AMGN now seen reaching $58. Estimates also increased on pricing power in the base business. Neutral rating. Apollo ( APOL) added to Conviction Buy List at Goldman. $62 price target. Company should see better enrollment growth. Arrow Electronics ( ARW) numbers lowered at Credit Suisse. Shares of ARW now seen reaching $39. Estimates also cut, as demand remains soft. Neutral rating. Borg Warner ( BWA) estimates, target raised at Citigroup. Shares of BWA now seen reaching $88. Estimates also raised on stronger top line performance and better conversion. Hold rating. CB Richard Ellis ( CBG) estimates, target lowered at Barclays. Shares of CBG now seen reaching $30. Estimates also lowered on lower terminal growth rate. Overweight rating. Colgate-Palmolive ( CL - Get Report) estimates lowered at UBS through 2012. Underlying fundamentals weaker and ability to forecast is deteriorating. Maintain $84 price target and Neutral rating. Coventry Health ( CVH) numbers increased at Barclays. CVH estimates were raised through 2012. Company boosted its guidance. Equal-weight rating and new $38 price target. Chevron ( CVX - Get Report) estimates, target increased at Barclays. Shares of CVX now seen reaching $135, according to Barclays. Estimates also raised on higher oil price leverage and relative valuation. Overweight rating. EQT Corporation ( EQT) estimates, target increased at Barclays. Shares of EQT now seen reaching $77, Barclays said. Estimates also increased on potential change to corporate structure. Overweight rating. Federated Investors ( FII) estimates, target reduced at Barclays. Shares of FII now seen reaching $24. Estimates also lowered on increased net fee waivers. Equal Weight rating.
Helmerich & Payne ( HP) numbers raised at Goldman. Shares of HP now seen reaching $80. Estimates also increased, as the company is executing on its newbuild strategy. Neutral rating. Helmerich & Payne estimates, target raised at UBS. Shares of HP now seen reaching $75. Estimates also raised to reflect additional newbuilds. Neutral rating. ITT ( ITT) estimates, target reduced at Goldman. ITT estimates were lowered through 2013. Company is realizing lower defense margins. Neutral rating and new $64 price target. LyondellBasell ( LYB) estimates increased at UBS through 2011. Strong Q2 beat. Maintain $47 price target and Buy rating. Marriott ( MAR) estimates, target reduced at Jefferies. MAR estimates were cut through 2012, Jefferies said. Company is facing multiple growth headwinds. Buy rating. Newell Rubbermaid ( NWL) numbers lowered at Morgan Stanley. Shares of NWL now seen reaching $20. Estimates also cut, as the company is generating less cash flow. Overweight rating. Owens-Illinois ( OI) numbers cut at Goldman. Shares of OI now seen reaching $28. Estimates also lowered, given the company's lower volume guidance. Neutral rating. Priceline.com ( PCLN) numbers raised at ThinkEquity. Shares of PCLN now seen reaching $725. Estimates also increased, as the company should continue to deliver solid growth. Buy rating. Sally Beauty ( SBH) numbers upped at Credit Suisse. SBH estimates were boosted through 2013. Company is seeing higher sales growth. Outperform rating and new $19 price target. Southwestern Energy ( SWN) numbers increased at Morgan Stanley. SWN estimates were raised through 2013, Morgan Stanley said. Company is realizing higher oil production. Neutral rating and new $51 price target. Torchmark ( TMK) estimates, target boosted at Credit Suisse. Shares of TMK now seen reaching $41. Estimates also upped, as the company is buying back more stock. Underperform rating. Weyerhaeuser ( WY) estimates lowered at UBS.WY estimates decreased through 2012. More conservative outlook on the housing recovery. Maintain $18 price target and Sell rating. End of report.